Allogeneic Transplantation in Multiple Myeloma

2004 ◽  
pp. 183-203
Author(s):  
Gösta Gahrton ◽  
Kenneth C. Anderson ◽  
William Bensinger
Keyword(s):  
Multiple Myeloma ◽  
Allogeneic Transplantation

Allogeneic Transplantation for the Treatment of Multiple Myeloma

2009 ◽  
pp. 261-279
Author(s):  
Rebecca L. Olin ◽  
Dan T. Vogl ◽  
Edward A. Stadtmauer
Keyword(s):  
Multiple Myeloma ◽  
Allogeneic Transplantation

Allogeneic Transplantation for Multiple Myeloma

2008 ◽  
pp. 125-142
Author(s):  
Fengrong Wang ◽  
Edmund K. Waller
Keyword(s):  
Multiple Myeloma ◽  
Allogeneic Transplantation

scholarly journals Novel Strategies for Immunotherapy in Multiple Myeloma: Previous Experience and Future Directions

2012 ◽  
Vol 2012 ◽  
pp. 1-28 ◽  
Author(s):  
Ivetta Danylesko ◽  
Katia Beider ◽  
Avichai Shimoni ◽  
Arnon Nagler
Keyword(s):  
Multiple Myeloma ◽  
Specific Antigen ◽  
Allogeneic Transplantation ◽  
Cellular Immunotherapy ◽  
Future Directions ◽  
Study Protocols ◽  
Immune Incompetence ◽  
Life Threatening ◽  
Dc Vaccines ◽  
Antigen Presenting

Multiple myeloma (MM) is a life-threatening haematological malignancy for which standard therapy is inadequate. Autologous stem cell transplantation is a relatively effective treatment, but residual malignant sites may cause relapse. Allogeneic transplantation may result in durable responses due to antitumour immunity mediated by donor lymphocytes. However, morbidity and mortality related to graft-versus-host disease remain a challenge. Recent advances in understanding the interaction between the immune system of the patient and the malignant cells are influencing the design of clinically more efficient study protocols for MM. Cellular immunotherapy using specific antigen-presenting cells (APCs), to overcome aspects of immune incompetence in MM patients, has received great attention, and numerous clinical trials have evaluated the potential for dendritic cell (DC) vaccines as a novel immunotherapeutic approach. This paper will summarize the data investigating aspects of immunity concerning MM, immunotherapy for patients with MM, and strategies, on the way, to target the plasma cell more selectively. We also include the MM antigens and their specific antibodies that are of potential use for MM humoral immunotherapy, because they have demonstrated the most promising preclinical results.

Advances in the Autologous and Allogeneic Transplantation Strategies for Multiple Myeloma

2011 ◽  
Vol 18 (4) ◽  
pp. 258-267 ◽  
Author(s):  
Taiga Nishihori ◽  
Melissa Alsina
Keyword(s):  
Multiple Myeloma ◽  
Allogeneic Transplantation

Allogeneic transplantation in multiple myeloma

2014 ◽  
Vol 7 (1) ◽  
pp. 79-90 ◽  
Author(s):  
Gösta Gahrton ◽  
Amrita Krishnan
Keyword(s):  
Multiple Myeloma ◽  
Allogeneic Transplantation

scholarly journals Syngeneic transplantation in multiple myeloma – a case-matched comparison with autologous and allogeneic transplantation

1999 ◽  
Vol 24 (7) ◽  
pp. 741-745 ◽  
Author(s):  
G Gahrton ◽  
◽  
H Svensson ◽  
B Björkstrand ◽  
J Apperley ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Allogeneic Transplantation ◽  
Matched Comparison

scholarly journals Non-Myeloablative Conditioning and Allogeneic Transplantation for Multiple Myeloma

2009 ◽  
Vol 15 (2) ◽  
pp. 71
Author(s):  
K. Osman ◽  
B. Elliott ◽  
J. Mandeli ◽  
E. Scigliano ◽  
V. Ross-Dodds ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Allogeneic Transplantation ◽  
Myeloablative Conditioning
Sign in / Sign up

Export Citation Format

Share Document